<DOC>
	<DOC>NCT00266240</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients 3075 years of age; type 2 diabetes mellitus for &gt;3 months before screening; treatmentnaive, inadequately controlled diabetes despite diet and exercise, or inadequately controlled diabetes in patients on monotherapy or combination therapy (maximum of 2 oral antihyperglycemic medications). type 1 diabetes mellitus; women who are pregnant, breastfeeding or not using adequate contraceptive methods.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>